RecruitingAtopic Dermatitis (AD)
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
Sponsor: Daniel Kaplan
You may qualify if…
- ✓ Phase 1b:
- ✓ Patients 18 years or older at time of consent
- ✓ Mild-to-Moderate AD, defined as:
- ✓ BSA ≤ 10%
- ✓ IGA ≤ 3
- ✓ No past biologic therapy
- ✓ No systemic therapy for 3 months
- ✓ No topical therapy for treatment of AD for 4 weeks
You may not qualify if…
- ✕ Phase 1b:
- ✕ Age less than 18 years old
- ✕ Pregnant or breastfeeding
- ✕ Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure
- ✕ Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks
- ✕ Has used topical therapy for treatment of AD within 4 weeks
- ✕ Phase 2:
- ✕ Patients enrolled in Phase 1
Where it's recruiting
Pennsylvania
Pittsburgh
Source: ClinicalTrials.gov · NCT06928246 · last updated 2026-05-04